Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study
- 25 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (7) , 960-965
- https://doi.org/10.1161/01.cir.0000050600.49419.25
Abstract
Background— The HOPE study has demonstrated that ramipril is beneficial (ie, prevents cardiovascular death, myocardial infarction, and stroke) for a broad range of patients without evidence of left...Keywords
This publication has 6 references indexed in Scilit:
- Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticiansStatistics in Medicine, 2000
- ACE Inhibition in Cardiovascular DiseaseNew England Journal of Medicine, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- The Progressive Cost of Complications in Type 2 Diabetes MellitusArchives of internal medicine (1960), 1999
- The Distribution of Health Care Costs and Their Statistical Analysis for Economic EvaluationJournal of Health Services Research & Policy, 1998
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993